Range Cancer Therapeutics Index (CNCR)

$14.36 0.21 (1.44%)

16:15 EDT CNCR Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 1,766

Day's Range $14.36 - $14.63

52-Week Range $9.22 - $17.96

Dividend & Yield N/A (N/A)

CNCR Stock Predictions, Articles, and Range Cancer Therapeutics Index News

From the Web

3 Promising Oncology Stocks To Consider Adding To Your Portfolio

From Talk Markets Jun 14, 2021

With tech integration and DNA sequencing increasing the efficacy of potential cancer drugs in the pipeline, we believe biotech names AstraZeneca, Amgen and Incyte are worth adding to a portfolio.

4 Promising Oncology Stocks to Consider Adding to Your Portfolio

From StockNews.com Jun 11, 2021

The Biotech industry has been working to develop cancer treatments for a long time. But now, with tech integration and DNA sequencing increasing the efficacy of potential cancer drugs in the pipeline, we believe biotech names AstraZeneca (AZN), Amgen (AMGN), Incyte (INCY), and Champions Oncology (CSBR) are valuable additions to one’s portfolio now. So, let’s examine these companies more closely.

Best Biotech Stocks & ETFs for mRNA, Gene Editing

From Talk Markets Apr 30, 2021

2020 was the most challenging year in decades but it was great for scientific innovation, particularly in the biotech space.

Sector Watch: More oncology events as cancer ETF breaks out (NASDAQ:CNCR)

From Seeking Alpha Sep 20, 2020

Health Care, and more specifically oncology, will continue to gain attention with the events on the calendar this week.The Sachs 20th Annual Biotech in Europe Forum runs from Monday to Thursday. Monday, morning, Amgen (NASDAQ:AMGN) will present results from a Phase 1 Study of AMG 160 for prostate cancer as part of the European Society of Medical Oncology Virtual Congress.And Tuesday morning, Merck, whose oncology division has outperformed competitors over the last few years, is hosting an Oncology Virtual IR Briefing as part of ESMO 2020, according to Seeking Alpha's Catalyst Watch.A wave of deals in the cancer-treatment space has sparked sharp rallies across biotech. The big trigger last week was Gilead Sciences (NASDAQ:GILD) agreeing to acquire Immunomedics (NASDAQ:IMMU) in a transaction that values Immunomedics at ~$21B, giving Gilead Trodelvy, used to treat certain forms of breast cancer and being evaluated for a number of other cancers.On Friday, Piper Sandler issued a list of biotechs that could be in the sights of acquirers for their oncology treatment.

6 Sector ETFs Surviving the Market Rout

From Talk Markets Sep 15, 2020

Amid the uncertainties, a few sectors have survived last week’s turmoil. Here are six of that could be compelling picks for the weeks ahead as long as volatility persists.

5 ETFs Jump After Three-Day Rout: Will The Rally Last?

From Talk Markets Sep 10, 2020

Here are the ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.

ADVERTISEMENT